Interview with Dominique Demolle , Co-founder & CEO, Aepodia
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Address: Avenue Albert Einstein 2A
1348 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 39 20 11
Web: http://http/www.aepodia.com
Aepodia S.A. (spin-off of a top 10 US Pharma Company) was created in March 2007 by a group of experts in early-phase clinical development. Since then, our company has grown and built a strong and a worldwide reputation in the early clinical drug development sector. We have established solid and effective collaborations with world pharmaceutical leaders, as well as with small biotech companies. The management and staff members have a background in pharmaceutical development that allows us to understand sponsor requirements and challenges and to meet their needs in an optimal way.
Our headquarters are located in Louvain-La-Neuve, Belgium, with offices in Paris-La Défense, France. Thanks to our strategic location in the center of Europe, we can cover the European phase I units. We also support clinical trials in the United-States and Singapore and provide easy access to patients.
Aepodia is a CRO sponsor representative providing customized services in Phase I/II clinical trials and in clinical development of Medical devices.
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
See our Cookie Privacy Policy Here
